Mutual of America Capital Management LLC Sells 2,100 Shares of Neurocrine Biosciences, Inc. $NBIX

Mutual of America Capital Management LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,217 shares of the company’s stock after selling 2,100 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Neurocrine Biosciences were worth $6,186,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of NBIX. Geneos Wealth Management Inc. grew its holdings in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. WPG Advisers LLC purchased a new stake in Neurocrine Biosciences in the first quarter worth about $32,000. Smallwood Wealth Investment Management LLC purchased a new stake in Neurocrine Biosciences in the first quarter worth about $34,000. SVB Wealth LLC purchased a new stake in Neurocrine Biosciences in the first quarter worth about $35,000. Finally, Golden State Wealth Management LLC grew its holdings in Neurocrine Biosciences by 116.9% in the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock worth $44,000 after purchasing an additional 214 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 106,322 shares of the firm’s stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total value of $13,440,164.02. Following the sale, the director owned 514,596 shares in the company, valued at approximately $65,050,080.36. This trade represents a 17.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 0.9%

Shares of NBIX opened at $142.65 on Wednesday. The company has a market capitalization of $14.15 billion, a P/E ratio of 42.20, a price-to-earnings-growth ratio of 1.01 and a beta of 0.21. The firm has a 50 day moving average of $139.27 and a 200 day moving average of $126.68. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $154.61.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.08. The company had revenue of $687.50 million during the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The firm’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.63 earnings per share. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Guggenheim upped their price objective on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on shares of Neurocrine Biosciences from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. Citigroup began coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They set a “buy” rating and a $175.00 price target for the company. Finally, Zacks Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus price target of $164.32.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.